-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Genmab, Raises Price Target to $57

Benzinga·10/30/2026 18:05:25
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and raises the price target from $42 to $57.